Details for Patent: 11,661,441
✉ Email this page to a colleague
Which drugs does patent 11,661,441 protect, and when does it expire?
Patent 11,661,441 protects SYFOVRE and EMPAVELI and is included in two NDAs.
This patent has thirty patent family members in twelve countries.
Drugs Protected by US Patent 11,661,441
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN | ⤷ Try a Trial | |||
Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,661,441
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2012253294 | ⤷ Try a Trial | |||
Australia | 2017245334 | ⤷ Try a Trial | |||
Australia | 2019226186 | ⤷ Try a Trial | |||
Brazil | 112013028816 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |